Ardelyx's IBS-C drug reduces abdominal pain, increases bowel movements — 4 insights

Ardelyx's Tenapanor met its primary endpoint of reducing abdominal pain while increasing bowel movements during its second phase late-stage trial, Reuters reports.

Here's what you should know:

1. The drug treats irritable bowel syndrome with constipation.

2. Ardelyx intends to file for marketing approval with the FDA in the second half of 2018.

3. Patients who were treated with Tenapanor experienced reduced abdominal pain by at least 30 percent. Patients also had more frequent bowel movements.

4. Tenapanor did increase the risk of diarrhea occurrence but only up to 16 percent. Reuters reports that wasn't a high enough percentage to limit the drug's effectiveness.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast